Monoclonal Antibodies (MAs) Global Market Report 2024

The monoclonal antibodies (mabs) market size has grown rapidly in recent years. It will grow from $234.37 billion in 2023 to $261.66 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. Historical growth in the use of monoclonal antibodies (MABs) can be linked to several factors, including the rising prevalence of chronic diseases, increased investment in research and development (R&D), a growing awareness of the benefits of MABs, and the expanding elderly population's healthcare needs.

The monoclonal antibodies (mabs) market size is expected to see rapidly grown in the next few years. It will grow to $424.24 billion in 2028 at a compound annual growth rate (CAGR) of 12.8%. Anticipated growth in the forecast period for monoclonal antibodies (MABs) is tied to several key factors, including the expansion of therapeutic applications, the rise of personalized medicine approaches, the development of biosimilars and generics, the utilization of combination therapies, increased focus on pandemic preparedness, and heightened investment in biopharmaceuticals.

The escalation of cost-efficient biosimilar monoclonal antibodies stands as a pivotal driver propelling the monoclonal antibody market's expansion. Biosimilars, designed to counter escalating healthcare costs and governmental pressures for reduced medication expenses, replicate biological drugs at a lower cost, with biosimilar monoclonal antibodies costing 20%-25% less than their original counterparts. The streamlined clinical trial processes for biosimilars contribute to their cost efficiency. India's 'Guidelines on Similar Biologics' by the Central Drugs Standard Control Organization (CSDCO) augur a significant uplift for the Indian biosimilar drug industry.

The escalating prevalence of chronic diseases emerges as a catalyst driving the monoclonal antibodies (mAbs) market. Chronic conditions, uncurable but manageable, have seen increased treatment with mAbs, particularly in managing dysregulated immune responses and inflammation. Shockingly, the World Health Organization's September 2023 data revealed that 74% of global deaths, amounting to 41 million annually, are due to noncommunicable diseases (NCDs) or chronic diseases. These staggering figures, with 86% of premature NCD-related deaths occurring in low- and middle-income countries, underscore the pivotal role of mAbs in addressing chronic ailments. The market has witnessed numerous strategic initiatives, with top companies leveraging acquisitions, collaborations, and partnerships to expand product portfolios and global reach. In March 2022, Collaborations like Sanofi S.A.'s collaboration with Seagen Inc. To develop cancer-targeting antibody-drug conjugates (ADCs) and Boehringer Ingelheim's partnership with MabGenesis, Inc. For therapeutic monoclonal antibodies exemplify this trend. Additionally, innovative technologies like RenMice, pioneered by Biocytogen Pharmaceuticals, are revolutionizing antibody-based therapies by offering a range of fully human antibodies and T-cell receptor mice with proprietary intellectual property.

Major companies operating in the monoclonal antibodies market are introducing innovative technologies such as RenMice to gain a competitive edge in the market. RenMice offers strong assistance in the exploration of various antibody-based therapies, including fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies. For instance, in September 2023, Biocytogen Pharmaceuticals, a China-based international biotech company that drives the research and development of new drugs with innovative technologies launched RenMice series, encompassing a selection of independently created fully human antibody mice and TCR mice, all of which possess proprietary intellectual property.

The regulatory support from the U.S. Food and Drug Administration (FDA) has significantly contributed to market growth, especially in the rare disease treatment segment. Accelerated approvals granted to drugs like avelumab (BAVENCIO) for metastatic Merkel cell carcinoma (MCC) and TECENTRIQ (atezolizumab) for locally-advanced or metastatic urothelial carcinoma (MUC) underscore the FDA's pivotal role in advancing monoclonal antibody therapeutics, fostering market expansion, and addressing critical medical needs.

Major companies operating in the monoclonal antibodies (MABS) market include Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Mylan N.V., Novo Nordisk A/S, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., Troikaa Pharmaceuticals Ltd., CD BioSciences Inc., Kanto Corporation, Molecular Depot LLC, Epigentek Group Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Diagnostic BioSystems Inc., Tonbo Biosciences Inc., Abraxis LLC, GlaxoSmithKline plc.

North America was the largest region in the monoclonal antibodies (MAbS) market in 2023. The regions covered in the monoclonal antibodies (MABS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the monoclonal antibodies (MABS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

There are several sources of monoclonal antibodies: murine, chimeric, humanized, and fully human. Murine antibodies contain two types of chains, one from a mouse and the other from a human. The prefix 'o-' in the International Nonproprietary Name (INN) identifies murine antibodies. They find applications in various fields such as anti-cancer treatments, immunology, anti-infective therapies, neuropharmacology, cardiovascular and cerebrovascular conditions. These antibodies are utilized across different sectors including hospitals, private clinics, and research institutes.

The monoclonal antibodies (MABS) market research report is one of a series of new reports provides monoclonal antibodies (MABS) market statistics, such as industry global market size, regional shares, competitors with a monoclonal antibodies (MABS) market share, detailed monoclonal antibodies (MABS) market segments, market trends and opportunities, and any additional data you may require to thrive in the monoclonal antibodies (MABS) industry. This monoclonal antibody (MABS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.